CLR 131 在患有复发性或难治性恶性肿瘤(包括但不限于神经母细胞瘤、横纹肌肉瘤、尤文氏肉瘤和骨肉瘤)的儿童、青少年和年轻成人中的剂量递增研究 (CLOVER-2)
CLR 131 在患有特定实体瘤、淋巴瘤和恶性脑肿瘤的儿童、青少年和年轻人中的开放标签、剂量递增、疗效和安全性研究
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.
研究概览
详细说明
Even with standard, highly toxic multimodality therapies and salvage regimen, most pediatric patients with primary metastatic or relapsed solid tumors are confronted with a poor prognosis. For these patients there is currently no accepted successful treatment regimen. There is a need for new drugs, including targeted radiopharmaceuticals, preferably with cancer-specific uptake and broad applicability for these rare pediatric malignancies.
CLR 131 is a radioiodinated therapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted small-molecule compound (CLR1404) is radiolabeled with the isotope iodine-131 (I-131). CLR 131 has demonstrated tumor selective uptake across numerous adult and pediatric cancer cell types. Therapeutic efficacy has been demonstrated in various pediatric and adult-type cancer xenograft models, confirming the ability of CLR 131 to target tumors.
Based on the critical unmet medical need for effective agents with novel mechanisms of action in relapsed pediatric cancers and initial preclinical and clinical experience with radioiodinated CLR1404, Cellectar Biosciences has chosen to assess CLR 131 in a phase 1 pediatric trial.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G1X8
- Hospital for Sick Children
-
-
-
-
New South Wales
-
Westmead、New South Wales、澳大利亚、2145
- Children's Hospital at Westmead
-
-
-
-
California
-
Palo Alto、California、美国、94304
- Lucile Packard Children's Hospital
-
-
New York
-
New York、New York、美国、10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27708
- Duke University
-
-
Ohio
-
Cincinnati、Ohio、美国、45229
- Cincinnati Children's Hospital Medical Center
-
-
Texas
-
Houston、Texas、美国、77030
- Texas Children's Hospital
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- University of Wisconsin Hospital and Clinics
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
All Patients
- Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or radiographically suspected to be relapsed, refractory, or recurrent for which there are no standard treatment options with curative potential. Note: patients with diffuse intrinsic pontine glioma (DIPG) may enroll without histological or cytological confirmation.
- ≥ 2 years of age and ≤ 25 years of age at time of consent/assent
- If ≥ age 16 years, Karnofsky performance status of ≥ 60. If < age 16 years, Lansky performance status ≥ 60
- Platelets ≥ 75,000/µL (last transfusion, if any, must be at least 1 week prior to study registration, and, unless deemed medically necessary, no transfusions are allowed between registration and dosing)
- Absolute neutrophil count ≥ 750/µL
- Hemoglobin ≥ 8 g/dL (last transfusion must be at least 1 week prior to study registration, and, unless deemed medically necessary, no transfusions are allowed between registration and dosing)
- Using the bedside Schwartz formula, estimated GFR (creatinine clearance) > 60 ml/min/1.73m2
- Alanine aminotransferase < 3 × ULN
- Bilirubin < 2 × ULN
- Patients who have undergone autologous or allogeneic bone marrow transplant must be at least 3 months from transplant.
- Patients enrolling at total dose levels > 30 millicurie (mCi)/m2 must have availability or ability to collect an autologous hematopoietic stem cell back-up product prior to CLR 131 administration. At minimum, 2 x 10^6/kg cryopreserved CD34+ cells must be available.
- Patient or his or her legal representative is judged by the Investigator to have the initiative and means to be compliant with the protocol.
Patients with Pediatric Solid Tumor or Lymphoma
- At least 1 measurable lesion with longest diameter of at least 10 mm. Patients with a lesion(s) that are determined to be Metaiodobenzylguanidine (MIBG) or positron emission tomography (PET) positive may be enrolled at the investigator's discretion, even if not associated with a measurable lesion of at least 10 mm. Patients with neuroblastoma who have detectable disease may enroll provided they meet the requirements of the International Neuroblastoma Response Criteria.
- Patients with known brain metastases must have completed any radiotherapy or systemic treatments for brain metastases prior to enrollment; by investigator assessment be considered stable with no new signs or symptoms for at least 1 month, and on a stable dose of steroids (unchanged for three weeks prior to registration or on a steroid tapering regimen).
Patients with Recurrent or Refractory Brain Tumors
- At least 1 measurable lesion with longest diameter of at least 10 mm on any imaging sequence.
- Patients with previously known neurological deficits must be clinically stable at time of enrollment and able to complete all study related procedures. Patients with documented or newly diagnosed neurological deficits will be enrolled at the investigator's discretion.
- If patient receives steroids for neurological symptom control, the dose must be stable (unchanged for three weeks prior to registration) or on a steroid tapering regimen. Initiation of steroids per routine care immediately prior to CLR 131 dosing is acceptable.
Exclusion Criteria:
- Patients receiving active treatment for central nervous system metastases or those that are likely to require active treatment during anticipated participation in this trial. Patients with stable brain metastases treated with steroids may enroll at the investigator's discretion
- For solid tumor and lymphoma patients only, central nervous system involvement unless previously treated with surgery, systemic therapy, or radiotherapy with the patient neurologically stable. Patients with metastatic brain tumors that have been previously treated are allowed, provided the patient is neurologically stable (determined at the investigator's discretion).
- Antitumor therapy or investigational therapy, within 2 weeks of dosing. For certain types of radiation (craniospinal, total abdominal, whole lung [spot irradiation to skull-based metastases is not considered craniospinal radiation for the purposes of this study]), at least 3 months must have elapsed. No washout is required for palliative focal radiation. NOTE: Patients participating in non-interventional clinical trials (i.e., non-drug) are allowed to participate in this trial
- Patients previously treated with iodine-131 (131I)-MIBG who have already received a cumulative I-131 dose > 54 mCi/kg or who would exceed 54 mCi/kg by participating in this trial, are not eligible.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:CLR 131
CLR 131 intravenous administration |
IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with dose limiting toxicities (DLT)
大体时间:up to 64 days
|
DLT will be assessed by physical examination, vital signs, and laboratory values |
up to 64 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Identification of recommended phase 2 dose of CLR 131 in children, adolescents, and young adults
大体时间:until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
|
Dose and regimen to be used in Phase 2 trials of CLR 131 in children, adolescents, and young adults |
until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
|
|
Determination of preliminary antitumor activity of CLR 131 in children, adolescents, and young adults
大体时间:through Day 85
|
Response assessment per applicable criteria (e.g., Neuroblastoma Response Criteria (modified); RECIST 1.1; positron emission tomography response criteria in solid tumors (PERCIST); RANO) |
through Day 85
|
|
Determination of therapeutic activity of CLR 131 in children, adolescents, and young adults
大体时间:up to 22 days post initial infusion
|
Assessment via 131-I/CLR 131 SPECT/CT scans |
up to 22 days post initial infusion
|
|
Determination of event free survival following CLR 131 infusion in children, adolescents, and young adults
大体时间:1 month to 5 years
|
Time from first infusion of CLR 131 until progression or recurrence of disease |
1 month to 5 years
|
|
Determination of overall survival following CLR 131 infusion in children, adolescents, and young adults
大体时间:1 month to 5 years
|
Time from first infusion of CLR 131 until death due to any reason |
1 month to 5 years
|
|
Determine dosimetry of CLR 131 in children, adolescents, and young adults
大体时间:up to 15 days post initial infusion
|
Assessment of dosimetry via whole body planar imaging |
up to 15 days post initial infusion
|
合作者和调查者
调查人员
- 研究主任:Jarrod Longcor、Cellectar Biosciences
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 脑部疾病
- 中枢神经系统疾病
- 神经系统疾病
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 男性泌尿生殖系统疾病
- 肾脏疾病
- 泌尿系统疾病
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 先天性遗传病
- 免疫系统疾病
- 组织学类型的肿瘤
- 肿瘤、腺体和上皮
- 淋巴系统疾病
- 淋巴增生性疾病
- 免疫增生性疾病
- 泌尿系肿瘤
- 星形细胞瘤
- 神经外胚层肿瘤
- 肿瘤、生殖细胞和胚胎
- 肿瘤,神经组织
- 神经系统肿瘤
- 肾脏肿瘤
- 遗传性肿瘤综合征
- 肿瘤、结缔组织和软组织
- 神经外胚层肿瘤,原始的,外周的
- 肿瘤,骨组织
- 肿瘤,结缔组织
- 中枢神经系统肿瘤
- 肿瘤,肌肉组织
- 肿瘤,复杂和混合
- 肌肉瘤
- 脑肿瘤
- 脑干肿瘤
- 幕下肿瘤
- 先天性、遗传性和新生儿疾病和异常
- 半身和淋巴疾病
- 弥漫性脑桥脑胶质瘤
- 淋巴瘤
- 胶质母细胞瘤
- 胶质瘤
- 成神经细胞瘤
- 肉瘤,尤因
- 淋巴瘤,非霍奇金
- 肉瘤
- 霍奇金病
- 肉瘤,滑膜
- 横纹肌肉瘤
- 胶质肉瘤
- 骨肉瘤
- 室管膜瘤
- 髓母细胞瘤
- 神经外胚层肿瘤,原发性
- 肾母细胞瘤
- 横纹肌瘤
- 促纤维增生性小圆细胞瘤
- 肿瘤,神经上皮
- CLR1404
其他研究编号
- DCL-17-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.